03 August 2020
Visiongain has launched a new pharma report Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030: Forecasts by Solution (Enterprise Manufacturing System (EMS), Inventory Management System (IMS), Laboratory Information Management System (LIMS), Logistics Management System (LMS), Patient Management System (PMS), Quality Management System (QMS), Tracking and Tracing System (TTS), Cell Orchestration Platform (COP)), Deployment (On-cloud, Premises), End-user (Bio Bank, Hospital, Cell Therapy Lab, Others), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Plus Analysis of Leading Cell and Gene Supply Chain Services and Solutions Companies.
“With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies. Almost everything is going digital, and most of the companies have adopted a virtual approach and digitalization of supply chain is the optimum choice to keep the business running. Due to the present uncertainty across the supply chain, more and more players are expected to adopt digital solutions for managing the cell and gene therapy supply chain. There are more 160 software-enabled systems solutions which have been developed and introduced for the management of cell and gene advanced therapies supply chain.”
Industry Analyst, Visiongain 2020
This report evaluates the cell and gene supply chain services and solutions market for the period, 2020-2030. The global market is estimated to be worth US$ xx million in 2020 and is projected to reach US$ xx million in 2030 while growing at a CAGR of xx% over the forecast period from 2020 to 2030. The global cell and gene supply chain services and solutions market is anticipated to witness low CAGR of xx% from 2020 to 2025 as compared to CAGR of xx% during the second half of the forecast period i.e. 2025 to 2030. Visiongain anticipates that the overall CAGR for cell and gene supply chain services and solutions market will be xx% from 2020 to 2030.
An increase in the incidence of cardiovascular diseases, a rise in the demand for chimeric antigen receptor (CAR) T cell therapy, and an increase in the development of stem cell therapy approaches are expected to drive the market's growth. However, bottlenecks experienced by manufacturers during the commercialization of cell therapies and high costs associated with cell therapies are restraining the market's growth. Also, the rise in the development of allogeneic cell therapy is expected to offer lucrative opportunities for the market's growth. The growing use of allogeneic cell therapy which involves chemo radiotherapeutic conditioning therapy, followed by transplantation of hematopoietic stem cells as well as lymphocytes isolated from allogeneic healthy donors for treatment of various chronic diseases is expected to drive the cell and gene therapy services and solutions market in the coming years.
In March 2020, as the COVID-19 pandemic started spreading across various countries, various companies in the cell and gene therapy market are investing in the space. To expand its biopharma capabilities, Thermo Fisher invested USD 475 million to open a cell therapy development and manufacturing collaboration center in Princeton. To support cell therapy development of process development and increase the fabrication of viral vectors, Univercells launched the contract development and manufacturing organization (CDMO), Exothera. Furthermore, Gamma Biosciences invested over €50 million to expedite the development of Univercells’ manufacturing technology, which can reduce the viral vector production costs for gene therapies. Such developments are expected to push the cell and gene therapy supply chain market during the COVID-19 pandemic and in the coming few years as well.
With the growing number of COVID-19 infections all over the world, the cell and gene therapy treatment has become more promising and there may be a possible treatment from such therapies shortly. The pandemic has led to the high demand for cell and gene therapy using intravenous immunoglobulin (IVIG) for COVID-19 treatment. There is a possibility that immunoglobulin products and cellular products can be used for the treatment of seriously ill patients infected with COVID-19 and expedite their recovery process. With the growing need for a new treatment for COVID-19, well-designed clinical trials are very essential and cell and gene therapy play a vital role. This has impacted the cell and gene therapy supply chain positively, as there is a boost in the demand for such treatments.
Some of the major companies operating in the global cell and gene supply chain services and solutions market are BioLifeSolutions Inc., Be The Match BioTherapies, Cryoport Systems, Inc., McKesson Corporation, MasterControl, Inc., Veeva Systems, TrakCel, WellSky, STEMSOFT Software, and Vineti among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.